Regeneron, Ultragenyx Ink International Deal on Cholesterol Drug Evkeeza
January 07 2022 - 7:49AM
Dow Jones News
By Colin Kellaher
Regeneron Pharmaceuticals Inc. and Ultragenyx Pharmaceutical
Inc. on Friday said they signed an international licensing
agreement for Regeneron's cholesterol drug Evkeeza.
Under the agreement, Ultragenyx, a Novato, Calif.,
biopharmaceutical company, will develop, commercialize and
distribute Evkeeza in countries outside the U.S., including in the
European Economic Area, where Evkeeza was approved in June
2021.
Regeneron will receive a $30 million upfront payment and is
eligible to receive up to $63 million in potential regulatory and
sales milestones, the companies said.
Tarrytown, N.Y., biotechnology company Regeneron discovered
Evkeeza and launched the drug in the U.S. last February for
patients with homozygous familial hypercholesterolemia, an
ultra-rare inherited form of high cholesterol. Regeneron said it
will continue to solely sell Evkeeza in the U.S.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 07, 2022 07:34 ET (12:34 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024